Real-World study tracks Ozanimod's Long-Term impact on MS patients
NCT ID NCT05335031
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study followed 450 people with relapsing-remitting multiple sclerosis (RRMS) in Germany who were already prescribed ozanimod (Zeposia). Over three years, researchers collected data on how long patients stayed on the drug, its effect on quality of life, and any side effects. The goal was to see how well the medication works outside of a controlled clinical trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ozanimod (Zeposia)
What this could lead to
If successful, this study could confirm that ozanimod is a practical, long-term option for managing relapsing-remitting MS in real-world settings.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new treatment, only gathers data on existing use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universitätsklinikum Dresden, MS Ambulanz
Dresden, Saxony, 01307, Germany